Simple proof of confidentiality for private quantum channels in noisy environments

Complete security proofs for quantum communication protocols can be notoriously involved, which convolutes their verification, and obfuscates the key physical insights the security finally relies on. In such cases, for the majority of the community, the utility of such proofs may be restricted. Here we provide a simple proof of confidentiality for parallel quantum channels established via entanglement distillation based on hashing, in the presence of noise, and a malicious eavesdropper who is restricted only by the laws of quantum mechanics. The direct contribution lies in improving the linear confidentiality levels of recurrence-type entanglement distillation protocols to exponential levels for hashing protocols. The proof directly exploits the security relevant physical properties: measurement-based quantum computation with resource states and the separation of Bell-pairs from an eavesdropper. The proof also holds for situations where Eve has full control over the input states, and obtains all information about the operations and noise applied by the parties. The resulting state after hashing is private, i.e., disentangled from the eavesdropper. Moreover, the noise regimes for entanglement distillation and confidentiality do not coincide: Confidentiality can be guaranteed even in situation where entanglement distillation fails. We extend our results to multiparty situations which are of special interest for secure quantum networks.Comment: 5 + 11 pages, 0 + 4 figures, A. Pirker and M. Zwerger contributed equally to this work, replaced with accepted versio

Long-range big quantum-data transmission

We introduce an alternative type of quantum repeater for long-range quantum communication with improved scaling with the distance. We show that by employing hashing, a deterministic entanglement distillation protocol with one-way communication, one obtains a scalable scheme that allows one to reach arbitrary distances, with constant overhead in resources per repeater station, and ultrahigh rates. In practical terms, we show that also with moderate resources of a few hundred qubits at each repeater station, one can reach intercontinental distances. At the same time, a measurement-based implementation allows one to tolerate high loss, but also operational and memory errors of the order of several percent per qubit. This opens the way for long-distance communication of big quantum data.Comment: revised manuscript including new result

Generation of multi-modal dialogue for a net environment

In this paper an architecture and special purpose markup language for simulated affective face-to-face communication is presented. In systems based on this architecture, users will be able to watch embodied conversational agents interact with each other in virtual locations on the internet. The markup language, or Rich Representation Language (RRL), has been designed to provide an integrated representation of speech, gesture, posture and facial animation

Spatio-temporal gait analysis based on human-smart rollator interaction

The ability to walk is typically related to several biomechanical components that are involved in the gait cycle (or stride), including free mobility of joints, particularly in the legs; coordination of muscle activity in terms of timing and intensity; and normal sensory input, such as vision and vestibular system. As people age, they tend to slow their gait speed, and their balance is also affected. Also, the retirement from the working life and the consequent reduction of physical and social activity contribute to the increased incidence of falls in older adults. Moreover, older adults suffer different kinds of cognitive decline, such as dementia or attention problems, which also accentuate gait disorders and its consequences. In this paper we present a methodology for gait identification using the on-board sensors of a smart rollator: the i-Walker. This technique provides the number of steps performed in walking exercises, as well as the time and distance travelled for each stride. It also allows to extract spatio-temporal metrics used in medical gait analysis from the interpretation of the interaction between the individual and the i-Walker. In addition, two metrics to assess users’ driving skills, laterality and directivity, are proposed.Peer ReviewedPostprint (author's final draft

The land use change impact of biofuels consumed in the EU: Quantification of area and greenhouse gas impacts

Biofuels are promoted as an option to reduce climate emissions from the transport sector. As most biofuels are currently produced from land based crops, there is a concern that the increased consumption of biofuels requires agricultural expansion at a global scale, leading to additional carbon emissions. This effect is called Indirect Land Use Change, or ILUC. The EU Renewable Energy Directive (2009/28/EC) directed the European Commission to develop a methodology to account for the ILUC effect. The current study serves to provide new insights to the European Commission and other stakeholders about these indirect carbon and land impacts from biofuels consumed in the EU, with more details on production processes and representation of individual feedstocks than was done before. ILUC cannot be observed or measured in reality, because it is entangled with a large number of other changes in agricultural markets at both global and local levels. The effect can only be estimated through the use of models. The current study is part of a continuous effort to improve the understanding and representation of ILUC

A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo

Small-molecule EGFR inhibitors have distinctly improved the overall survival especially in EGFR-mutated lung cancer. However, their use is often limited by severe adverse effects and rapid resistance development. To overcome these limitations, a hypoxia-activatable Co(III)-based prodrug (KP2334) was recently synthesized releasing the new EGFR inhibitor KP2187 in a highly tumor-specific manner only in hypoxic areas of the tumor. However, the chemical modifications in KP2187 necessary for cobalt chelation could potentially interfere with its EGFR-binding ability. Consequently, in this study, the biological activity and EGFR inhibition potential of KP2187 was compared to clinically approved EGFR inhibitors. In general, the activity as well as EGFR binding (shown in docking studies) was very similar to erlotinib and gefitinib (while other EGFR-inhibitory drugs behaved different) indicating no interference of the chelating moiety with the EGFR binding. Moreover, KP2187 significantly inhibited cancer cell proliferation as well as EGFR pathway activation in vitro and in vivo. Finally, KP2187 proved to be highly synergistic with VEGFR inhibitors such as sunitinib. This indicates that KP2187releasing hypoxia-activated prodrug systems are promising candidates to overcome the clinically observed enhanced toxicity of EGFR-VEGFR inhibitor combination therapies

Future environmental and agricultural impacts of Brazil's Forest Code

The role of improving the enforcement of Brazil's Forest Code in reducing deforestation in the Amazon has been highlighted in many studies. However, in a context of strong political pressure for loosening environmental protections, the future impacts of a nationwide implementation of the Forest Code on both environment and agriculture remain poorly understood. Here, we present a spatially explicit assessment of Brazil's 2012 Forest Code through the year 2050; specifically, we use a partial equilibrium economic model that provides a globally consistent national modeling framework with detailed representation of the agricultural sector and spatially explicit land-use change. We test for the combined or isolated impacts of the different measures of the Forest Code, including deforestation control and obligatory forest restoration with or without environmental reserve quotas. Our results show that, if rigorously enforced, the Forest Code could prevent a net loss of 53.4 million hectares (Mha) of forest and native vegetation by 2050, 43.1 Mha (81%) of which are in the Amazon alone. The control of illegal deforestation promotes the largest environmental benefits, but the obligatory restoration of illegally deforested areas creates 12.9 Mha of new forested area. Environmental reserve quotas further protect 5.8 Mha of undisturbed natural vegetation. Compared to a scenario without the Forest Code, by 2050, cropland area is only reduced by 4% and the cattle herd by 8%. Our results show that compliance with the Forest Code requires an increase in cattle productivity of 56% over four decades, with a combination of a higher use of supplements and an adoption of semi-intensive pasture management. We estimate that the enforcement of the Forest Code could contribute up to 1.03 PgCO<sub>2</sub>e to the ambitious GHG emissions reduction target set by Brazil for 2030

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Background: The combination of paclitaxel with cisplatin or carboplatin has significant activity in non-small-cell lung cancer (NSCLC). This phase III study of chemotherapy-naïve advanced NSCLC patients was designed to assess whether response rate in patients receiving a paclitaxel/carboplatin combination was similar to that in patients receiving a paclitaxel/cisplatin combination. Paclitaxel was given at a dose of 200 mg/m2 (3-h intravenous infusion) followed by either carboplatin at an AUC of 6 or cisplatin at a dose of 80 mg/m2, all repeated every 3 weeks. Survival, toxicity and quality of life were also compared. Patients and methods: Patients were randomised to receive one of the two combinations, stratified according to centre, performance status, disease stage and histology. The primary analyses of response rate and survival were carried out on response-evaluable patients. Survival was also analysed for all randomised patients. Toxicity analyses were carried out on all treated patients. Results: A total of 618 patients were randomised. The two treatment arms were well balanced with regard to gender (83% male), age (median 58 years), performance status (83% ECOG 0-1), stage (68% IV, 32% IIIB) and histology (38% squamous cell carcinoma). In the paclitaxel/carboplatin arm, 306 patients received a total of 1311 courses (median four courses, range 1-10 courses) while in the paclitaxel/cisplatin arm, 302 patients received a total of 1321 courses (median four courses, range 1-10 courses). In only 76% of courses, carboplatin was administered as planned at an AUC of 6, while in 96% of courses, cisplatin was given at the planned dose of 80 mg/m2. The response rate was 25% (70 of 279) in the paclitaxel/carboplatin arm and 28% (80 of 284) in the paclitaxel/cisplatin arm (P = 0.45). Responses were reviewed by an independent radiological committee. For all randomised patients, median survival was 8.5 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm [hazard ratio 1.20, 90% confidence interval (CI) 1.03-1.40]; the 1-year survival rates were 33% and 38%, respectively. On the same dataset, a survival update after 22 months of additional follow-up yielded a median survival of 8.2 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm (hazard ratio 1.22, 90% CI 1.06-1.40; P = 0.019); the 2-year survival rates were 9% and 15%, respectively. Excluding neutropenia and thrombocytopenia, which were more frequent in the paclitaxel/carboplatin arm, and nausea/vomiting and nephrotoxicity, which were more frequent in the paclitaxel/cisplatin arm, the rate of severe toxicities was generally low and comparable between the two arms. Overall quality of life (EORTC QLQ-C30 and LC-13) was also similar between the two arms. Conclusions: This is the first trial comparing carboplatin and cisplatin in the treatment of advanced NSCLC. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment optio